ADMA Biologics(ADMA)
Search documents
ADMA LEGAL NOTICE: ADMA Biologics, Inc. is being Investigated for Securities Fraud after Auditor Resignation; Investors with Losses are Urged to Contact BFA Law (Nasdaq:ADMA)
GlobeNewswire News Room· 2024-10-15 10:11
NEW YORK, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into ADMA Biologics, Inc. (NASDAQ: ADMA) for potential violations of the federal securities laws. If you invested in ADMA Biologics, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/adma-biologics-inc. Why Did ADMA Biologics’s Stock Drop? ADMA Biologics is an end-to-end commercial biopharmaceutical company that manufactures, ...
ADMA SHAREHOLDER ALERT: ADMA Biologics, Inc. is Under Investigation for Securities Fraud after Auditor Resignation and 20% Stock Drop; Investors are Urged to Contact BFA Law (Nasdaq:ADMA)
GlobeNewswire News Room· 2024-10-13 11:23
NEW YORK, Oct. 13, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into ADMA Biologics, Inc. (NASDAQ: ADMA) for potential violations of the federal securities laws. If you invested in ADMA Biologics, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/adma-biologics-inc. Why Did ADMA Biologics’s Stock Drop? ADMA Biologics is an end-to-end commercial biopharmaceutical company that manufactures, ...
Johnson Fistel Begins Investigation into ADMA Biologics, Inc. Following a Significant Drop in the Company's Stock
GlobeNewswire News Room· 2024-10-11 13:25
SAN DIEGO, Oct. 11, 2024 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, LLP is investigating whether ADMA Biologics, Inc. (NASDAQ: ADMA) or any of its executive officers or others violated securities laws by misrepresenting or failing to timely disclose material, adverse information to investors. The investigation focuses on investors’ losses and whether they may be recovered under federal securities laws. What if I purchased ADMA Biologics securities? If you purchased securities and suffer ...
ADMA FRAUD ALERT: BFA Law is Investigating ADMA Biologics, Inc. for Securities Fraud after Stock Drops 20%; Investors with Losses are Urged to Contact the Firm (Nasdaq:ADMA)
GlobeNewswire News Room· 2024-10-11 10:35
NEW YORK, Oct. 11, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into ADMA Biologics, Inc. (NASDAQ: ADMA) for potential violations of the federal securities laws. If you invested in ADMA Biologics, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/adma-biologics-inc. Why Did ADMA Biologics’s Stock Drop? ADMA Biologics is an end-to-end commercial biopharmaceutical company that manufactures, ...
5 Stocks With Recent Price Strength Amid October Volatility
ZACKS· 2024-10-11 10:11
October generally remains volatile on Wall Street. This year, volatility has gripped in U.S. stock markets from the beginning of this month. October’s volatility is expected to persist due to a better-than-expected jobs data for September, expectations of a Fed rate cut in a gradual fashion rather than more aggressive way, a jump in the yield of the benchmark 10-Year Treasury Note, intensified geopolitical conflict in the Middle East and the upcoming U.S. Presidential election on Nov. 5.Consequently, a hand ...
ADMA Biologics, Inc. Investors: Company Investigated by the Portnoy Law Firm
GlobeNewswire News Room· 2024-10-10 20:36
Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, Oct. 10, 2024 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises ADMA Biologics, Inc. (“ADMA Biologics” or “the Company”) (NASDAQ: ADMA) investors that the firm has initiated an investigation into possible securities fraud and may file a class action on behalf of investors. ADMA Biologics investors that lost money on their investment are encouraged to contact Lesley Portnoy, Esq. Investors are encouraged to ...
ADMA Biologics Investors Who Have Lost Money Should Contact Block & Leviton to Find Out How They Might Recover Money Through The Firm's Investigation
GlobeNewswire News Room· 2024-10-10 18:44
BOSTON, Oct. 10, 2024 (GLOBE NEWSWIRE) -- Block & Leviton is investigating ADMA Biologics, Inc. (Nasdaq: ADMA) for potential securities law violations. Investors who have lost money in their ADMA Biologics investment should contact the firm to learn more about how they might recover those losses. For more details, visit https://blockleviton.com/cases/adma. What is this all about? On October 10, 2024, shares of ADMA Biologics, Inc. fell nearly 20% following the Company's after-market announcement that its i ...
Adma Biologics (ADMA) Stock Dips While Market Gains: Key Facts
ZACKS· 2024-10-09 22:55
The most recent trading session ended with Adma Biologics (ADMA) standing at $20.33, reflecting a -1.91% shift from the previouse trading day's closing. The stock trailed the S&P 500, which registered a daily gain of 0.71%. At the same time, the Dow added 1.03%, and the tech-heavy Nasdaq gained 0.6%.The the stock of infectious disease drug developer has risen by 19.84% in the past month, leading the Medical sector's loss of 3.33% and the S&P 500's gain of 6.41%.The upcoming earnings release of Adma Biologic ...
New Strong Buy Stocks for October 7th
ZACKS· 2024-10-07 11:16
Here are five stocks added to the Zacks Rank #1 (Strong Buy) List today:ADMA Biologics (ADMA) : This specialty immune globulin company which develops, manufactures and intends to market plasma-based biologics for the treatment and prevention of certain infectious diseases, has seen the Zacks Consensus Estimate for its current year earnings increasing 40% over the last 60 days.Vertex (VERX) : This company which provides tax technology solutions for corporations in retail, leasing, communication and manufactu ...
ADMA Biologics: Riding High On ASCENIV's Success
Seeking Alpha· 2024-10-02 11:30
I specialize in biotech and healthcare investment analysis, integrating clinical expertise with a solid foundation in business strategy. My approach leverages detailed risk-return charts and DCF analyses to clearly communicate the investment potential and associated risks. I advocate for a barbell portfolio strategy, with 90% allocated to secure assets such as Treasuries and broad-market ETFs, and 10% to high-alpha stocks. This balanced approach ensures that all recommendations are made within a context of ...